Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: Aug 27, 2020 11:09AM
The DESTINY-Breast02 trial is a phase III trial for people diagnosed with metastatic HER2-positive breast cancer or other stages of HER2-positive disease that can't be removed with surgery and have been previously treated with Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine).
The trial is looking to see if the medicine fam-trastuzumab-deruxtecan-nxki offers more benefits than either Herceptin (chemical name: trastuzumab) and Xeloda (chemical name: capecitabine) or Tykerb (chemical name: lapatinib) and Xeloda.